A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ, Maiolatesi S, Patterson N, Sedegah M, Limbach K, Teneza-Mora N, Chuang I, Hollis-Perry KM, Banania JG, Guzman I, Ganeshan H, Reyes S, Hollingdale MR, Wong M, Lindstrom A, Reyes A, Alcorta Y, Garver L, Bankard K, Belmonte A, Belmonte M, Huang J, Gowda K, Inoue S, Velasco R, Bergmann-Leitner E, Hutter J, Lee T, Adams N, Chaudhury S, Hunt D, Tamminga C, Berrie E, Bellamy D, Bittaye M, Ewer K, Diggs C, Soisson LA, Lawrie A, Hill A, Richie TL, Villasante E, Epstein JE, Duplessis CA.
Sklar MJ, et al. Among authors: gowda k.
PLoS One. 2021 Sep 8;16(9):e0256980. doi: 10.1371/journal.pone.0256980. eCollection 2021.
PLoS One. 2021.
PMID: 34495988
Free PMC article.
Clinical Trial.